Trial Profile

A Phase III trial of AEVI-004

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fasoracetam (Primary)
Indications Attention-deficit hyperactivity disorder; Autistic disorder
Focus Therapeutic Use

Most Recent Events

03 Feb 2020 According to a Cerecor media release, the Aevi Genomic Medicine has been acquired and merged with the Cerecor.
26 Jul 2018 New trial record
19 Jul 2018 According to an Aevi Genomic Medicine media release, based on the data from Phase 2 ASCEND clinical trial and following minimal bridging preclinical and clinical pharmacological studies requested by FDA, the company anticipates initiating this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com